

Product datasheet for **SR302322**

Interferon alpha 2 (IFNA2) Human siRNA Oligo Duplex (Locus ID 3440)

Product data:

| | |
|---------------------|--|
| Product Type: | siRNA Oligo Duplexes |
| Purity: | HPLC purified |
| Quality Control: | Tested by ESI-MS |
| Sequences: | Available with shipment |
| Stability: | One year from date of shipment when stored at -20°C. |
| # of transfections: | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
| Note: | Single siRNA duplex (10nmol) can be ordered. |
| RefSeq: | NM_000605 |
| UniProt ID: | P01563 |
| Synonyms: | IFN-alpha-2; IFN-alphaA; IFNA; IFNA2B; IeIF A |
| Components: | IFNA2 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 3440) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml |
| Summary: | This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020] |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).